AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19460609
Drug: No clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No clopidogrel administration before CABG (Control)
Trial: 17089420
Drug: Behavioral Weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral Weight Loss Treatment (BWLT)
Trial: 8758833
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (30 min daily for 10 days at points PC6, LI4, ST36, RN4 and symptomatic points bilaterally)
Trial: 6985
Drug: Anxiety evocation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anxiety evocation during treatment
Trial: 28586628
Drug: Radial Extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial Extracorporeal Shock Wave Therapy (rESWT) combined with supervised exercises
Trial: 28586628
Drug: Sham Radial
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sham Radial Extracorporeal Shock Wave Therapy combined with supervised exercises
Trial: 28586628
Drug: Radial Extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial Extracorporeal Shock Wave Therapy (rESWT) in patients with calcification in rotator cuff
Trial: 22011856
Drug: Soybean-treated group
RxNorm normalized name: SOYBEAN
DrugBank: Soybean (DB10568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soybean-treated group (12.95 g of soy protein for 90 days)
Trial: 16416230
Drug: Mesalamine (2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalamine (2.4 g/day; n = 9)
Trial: 15477799
Drug: Statins (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statins (specific dosage and duration not mentioned)
Trial: 16399214
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone releasing hormone (GHRH)
Trial: 8012861
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide nasal spray (42 micrograms/nostril)
Trial: 8012861
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide nasal spray (168 micrograms/nostril)
Trial: 2557947
Drug: Pseudoephedrine 60
RxNorm normalized name: CTM 4/PSEUDOEPHEDRINE 60MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pseudoephedrine 60 mg plus ibuprofen 200 mg
Trial: 2557947
Drug: Pseudoephedrine 60
RxNorm normalized name: CTM 4/PSEUDOEPHEDRINE 60MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pseudoephedrine 60 mg alone
Trial: 1195153
Drug: Behavior therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavior therapy (maintenance follow-up)
Trial: 25893930
Drug: Lycopene 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lycopene 35 mg, selenium 55 µg, and green tea catechins 600 mg
Trial: 24090777
Drug: Prenatal exposure
RxNorm normalized name: Ardisia crenata root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenatal exposure to antiepileptic drugs (AED)
Trial: 24090777
Drug: No AED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No AED treatment during pregnancy
Trial: 17140280
Drug: Zolmitriptan 2.5
RxNorm normalized name: zolmitriptan 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolmitriptan 2.5 mg oral tablet
Trial: 12830602
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol 20 micrograms 2-hourly to a maximum of four doses (80 micrograms)
Trial: 12830602
Drug: Dinoprostone 1
RxNorm normalized name: dinoprostone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dinoprostone 1 mg inserted in the posterior fornix and repeated 6-hourly to a maximum of three doses
Trial: 12830602
Drug: Misoprostol (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (both oral and vaginal)
Trial: 9125276
Drug: Transdermal Patch
RxNorm normalized name: TRANSDERMAL PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal Patch (Dermestril 50, 4 mg E2, delivers 50 micrograms E2 daily)
Trial: 9125276
Drug: Oral Tablet
RxNorm normalized name: Oral Tablet
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Tablet (2 mg micronized E2, daily administration)
Trial: 28697253
Drug: Augment current
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augment current treatment with bupropion (n=506)
Trial: 22492518
Drug: Warfarin (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (target INR 2-3)
Trial: 24692475
Drug: Aspirin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (75 mg/d)
Trial: 22179601
Drug: Landiolol (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Landiolol (group L, n = 32)
Trial: 17364234
Drug: OSI-7904L 12
RxNorm normalized name: OSI-7904L
DrugBank: OSI-7904L (DB05457)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OSI-7904L 12 mg/m2 intravenously every 21 days
Trial: 17364234
Drug: 5-FU/LV (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-FU/LV (intravenous l-LV 200 mg/m2, bolus 5-FU 400 mg/m2 and a 46-h infusion of 5-FU 2,400 mg/m2) every 14 days
Trial: 16291062
Drug: Ertapenem (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertapenem (1 g daily; n=295)
Trial: 12122922
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of ketamine
Trial: 12122922
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of a weak opioid and an NMDA-receptor antagonist
Trial: 8560901
Drug: Simvastatin 10
RxNorm normalized name: simvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 10 mg/day (LDL < 195 mg/dl) or 20 mg/day (LDL > 195 mg/dl)
Trial: 3389862
Drug: 4 IU
RxNorm normalized name: Cholecalciferol/Vitamin E 14000 IU-34 IU Oral Wafer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 IU growth hormone three days a week (group 1)
Trial: 3389862
Drug: 1 IU
RxNorm normalized name: factor VIII 1 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 IU twice daily six days a week (group 3)
Trial: 28181206
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract (Symfona® forte 120 mg) twice-daily for 6 months
Trial: 21381497
Drug: Ultrasound-guided intra-articular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided intra-articular injection of hyaluronic acid products
Trial: 18156154
Drug: Robot-based hand
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot-based hand motor therapy emphasizing intense active movement repetition, attention, speed, force, precision, and timing, including virtual reality games for 3 weeks.
Trial: 18156154
Drug: Grasp task
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grasp task practiced during robotic therapy.
Trial: 9484356
Drug: Anti-indigestion drug
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-indigestion drug use
Trial: 8057411
Drug: Trazodone (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone (150 mg to 200 mg)
Trial: 3246169
Drug: 50 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/kg ceftriaxone (single dose)
Trial: 3246169
Drug: 50 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/kg ceftriaxone (3 consecutive days)
Trial: 27384040
Drug: Antimicrobial photodynamic
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial photodynamic therapy (aPDT) combined with conventional scaling and root planing (SRP)
Trial: 22222052
Drug: IFN α-2a
RxNorm normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IFN α-2a (180 μg once weekly) + weight-based RBV
Trial: 22222052
Drug: IFN α-2b
RxNorm normalized name: RAD-IFN-2B
DrugBank: Nadofaragene firadenovec (DB17381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN α-2b (1.5 μg/kg once weekly) + weight-based RBV
Trial: 23908086
Drug: Pioglitazone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (15 mg/d)
Trial: 16506273
Drug: Voglibose (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voglibose (0.6 mg/d)
Trial: 10551687
Drug: Abciximab plus
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abciximab plus low-dose heparin
Trial: 3056085
Drug: Fibraccel (50-ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibraccel (50-ml infusions lasting 30 min each, started immediately after antagonism by protamine chloride, followed by subsequent 50-ml infusions every 4 h until 20 h after extracorporeal circulation)
Trial: 3056085
Drug: Placebo infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusions at corresponding times
Trial: 30168511
Drug: Combined physiotherapy
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined physiotherapy including treatment in the spa capsule (n=29)
Trial: 30168511
Drug: Local vacuum
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local vacuum therapy (n=28)
Trial: 30168511
Drug: Transcranial magnetic
RxNorm normalized name: transcranial magnetic stimulator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial magnetic stimulation therapy (n=29)
Trial: 14574032
Drug: Pharmacologic antiarrhythmic
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacologic antiarrhythmic therapy
Trial: 10225168
Drug: Tramadol 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 1.5 mg kg‐1
Trial: 8903382
Drug: Colchicine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (1 mg/d, 5 days per week) + UDCA (13-15 mg x kg(‐1) x day(‐1))
Trial: 1864448
Drug: 150 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/day diclofenac potassium for 7 days
Trial: 1864448
Drug: 1.2 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 g/day ibuprofen
Trial: 27083135
Drug: 1% dextrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% dextrose in Ringer lactate (RL) at 10 ml·kg(‐1) ·h(‐1) (Group D1)
Trial: 27083135
Drug: 2% dextrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% dextrose in Ringer lactate (RL) at 10 ml·kg(‐1) ·h(‐1) (Group D2)
Trial: 27083135
Drug: 10% dextrose
RxNorm normalized name: Aminosyn II 4.25% in 10% Dextrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% dextrose in N/5 saline at 4 ml·kg(‐1) ·h(‐1) and replacement fluid with 6 ml·kg(‐1) ·h(‐1) of RL (Group D4)
Trial: 25096822
Drug: Lactose solution
DrugBank: Lactose (DB04465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose solution (25 g)
Trial: 17617338
Drug: Single vendor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single vendor implant selection
Trial: 10497961
Drug: Oral micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral micronized progesterone
Trial: 2174320
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion during hyperglycaemia
Trial: 2174320
Drug: Intralipid infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid infusion during hyperinsulinaemia with euglycemia or hyperglycaemia
Trial: 7239110
Drug: Starch enemas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starch enemas (10%; 1000 ml t.i.d.) plus neomycin tablets
Trial: 7239110
Drug: Lactose enemas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose enemas (20%; 1000 ml t.i.d.) plus placebo tablets
Trial: 7239110
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (starch enemas plus neomycin tablets)
Trial: 7239110
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (lactose enemas plus placebo tablets)
Trial: 30709694
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (no LED light irradiation)
Trial: 29565642
Drug: MRI evaluation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRI evaluation for both treatments
Trial: 25708531
Drug: Cal/BD ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cal/BD ointment
Trial: 11304721
Drug: 220 mg
RxNorm normalized name: urea 220 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 220 mg of naproxen sodium
Trial: 11304721
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of diphenhydramine hydrochloride
Trial: 11304721
Drug: 220 mg
RxNorm normalized name: urea 220 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 220 mg of naproxen sodium with 50 mg of diphenhydramine hydrochloride
Trial: 1430394
Drug: 0.5 ml
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ml of MPI 5003
Trial: 1430394
Drug: 0.25 ml
RxNorm normalized name: mineral oil 0.25 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 ml of MPI 5003
Trial: 18711764
Drug: Mitomycin (MMC)
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin (MMC) 8 mg/m(2) on day 1 and cisplatin (DDP) 25 mg/m(2) on days 1 to 3 with Kanglaite (KLT) 100 ml intravenously per day on days 1 to 14 every 3 weeks
Trial: 18711764
Drug: Mitomycin (MMC)
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin (MMC) 8 mg/m(2) on day 1 and cisplatin (DDP) 25 mg/m(2) on days 1 to 3 without Kanglaite (KLT)
Trial: 18711764
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with clinical benefit from chemotherapy
Trial: 15918104
Drug: Dual RAAS
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual RAAS blockade (angiotensin II receptor blocker + ACE inhibitor)
Trial: 12971702
Drug: Enhanced upper
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced upper limb therapy (intervention group)
Trial: 12971702
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group therapy
Trial: 12971702
Drug: Total amount
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total amount of inpatient physiotherapy and occupational therapy received by the intervention group
Trial: 11009238
Drug: Plain mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain mixture LBH (2.5 mL lidocaine 2%, 2.5 mL bupivacaine 0.5%, 5 IU/mL hyaluronidase, and 0.125 mL isotonic saline)
Trial: 11009238
Drug: pH-adjusted mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pH-adjusted mixture LBH-PH (2.5 mL lidocaine 2%, 2.5 mL bupivacaine 0.5%, 5 IU/mL hyaluronidase, and 0.125 mL sodium bicarbonate 8.4%)
Trial: 8769362
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) administration (0.1 IU/kg.d)
Trial: 8769362
Drug: T3 administration
RxNorm normalized name: T3
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: T3 administration (40 micrograms on even dates or 20 micrograms on uneven dates)
Trial: 1532948
Drug: 40% urea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40% urea ointment with 1% bifonazole (group A)
Trial: 1532948
Drug: 40% urea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40% urea ointment with 1% bifonazole and oral griseofulvin 500 mg/day (group B)
Trial: 1532948
Drug: Oral griseofulvin
RxNorm normalized name: Griseofulvin
DrugBank: Griseofulvin (DB00400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral griseofulvin alone
Trial: 25523961
Drug: Subgingival mechanical
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subgingival mechanical therapy with azithromycin
Trial: 25523961
Drug: Subgingival mechanical
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subgingival mechanical therapy with placebo
Trial: 22297666
Drug: Intensive glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive glycemic control (target range 80–110 mg/dl)
Trial: 22297666
Drug: Conservative glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative glycemic control (target range 140–180 mg/dl)
Trial: 10811588
Drug: Thrombolysis with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolysis with standard aspirin and beta-blockade
Trial: 8979037
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of both systems
Trial: 1599892
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg of morphine in 0.2 ml volume mixed with 0.75% bupivacaine and 0.2 ml 1:1000 epinephrine (Group 1, n = 40)
Trial: 1599892
Drug: Saline in
RxNorm normalized name: Simply Saline Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline in 0.2 ml volume mixed with 0.75% bupivacaine and 0.2 ml 1:1000 epinephrine (Group 2, n = 42)
Trial: 3881447
Drug: Closed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed treatment in a plaster cast
Trial: 28214082
Drug: Intravenous nicorandil
RxNorm normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nicorandil (6mg/h)
Trial: 26177235
Drug: Real rTMS
RxNorm normalized name: REAL FOODS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real rTMS (n = 10), 1200 pulses at 1 Hz for 20 min, five daily sessions over the contralesional motor cortex.
Trial: 17305206
Drug: Justice-based service
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Justice-based service recovery strategies (interactional justice, distributive justice, and combination)
Trial: 7572582
Drug: Mibefradil 25
RxNorm normalized name: mibefradil
DrugBank: Mibefradil (DB01388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mibefradil 25 mg
Trial: 9286850
Drug: Mibefradil (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mibefradil (all doses)
Trial: 9286850
Drug: Mibefradil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mibefradil (50 mg and 100 mg)
Trial: 3534592
Drug: L-PAM (melphalan)
RxNorm normalized name: L-PAM
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-PAM (melphalan) for 2 years
Trial: 29198406
Drug: Negative control
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative control (no aliskiren treatment)
Trial: 28664839
Drug: Paricalcitol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paricalcitol (2 µg/day for 24 weeks)
Trial: 18413499
Drug: Continuous Positive
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Positive Airway Pressure (CPAP) therapy for 4 weeks
Trial: 18413499
Drug: Control subjects
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control subjects (no CPAP therapy)
Trial: 10762497
Drug: Remacemide 600
RxNorm normalized name: Remacemide
DrugBank: Remacemide (DB06458)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remacemide 600 mg daily for 5 weeks
Trial: 10762497
Drug: Remacemide 150
RxNorm normalized name: Remacemide
DrugBank: Remacemide (DB06458)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remacemide 150 mg or 300 mg daily for 5 weeks
Trial: 7848615
Drug: Lisinopril (Women)
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril (Women)
Trial: 7848615
Drug: Lisinopril (Men)
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril (Men)
Trial: 2904203
Drug: topical timolol
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: topical timolol and betaxolol
Trial: 25853697
Drug: Endobronchial Coils
RxNorm normalized name: BOIL-EASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endobronchial Coils treatment
Trial: 21225292
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg 0.5% ropivacaine plus 25 μg fentanyl (group RF)
Trial: 21225292
Drug: 3.75 mg
RxNorm normalized name: zopiclone 3.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 mg 0.75% levobupivacaine plus 25 μg fentanyl (group LF)
Trial: 15454352
Drug: Beta-carotene (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene (50 mg/day)